Autopsy report · NCT00492388

Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

“Business decision not to continue development”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 2 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Hospira, now a wholly owned subsidiary of Pfizer

Sponsor type

Industry

Conditions

Pain; Cancer

Interventions

PMI-150 (intranasal ketamine); placebo

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump
  “The decision to terminate development activities was based on business needs and unrelated to any safety or efficacy concerns.” (70% match in meaning)
• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
  “The development was stopped due to company's strategy consideration” (70% match in meaning)
• Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC
  “Decision based on the development company's development policy” (64% match in meaning)
• The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
  “strategy terminates development, the decision is not due to any safety-related issues” (64% match in meaning)
• A Single and Multiple Ascending Dose Study of JNJ-64457744
  “Strategic business decision, not due to safety concerns” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.